Real-world evaluation of the safety and tolerability of abacavir/dolutegravir/lamivudine in an incarcerated population

Int J STD AIDS. 2019 Oct;30(12):1163-1168. doi: 10.1177/0956462419863925. Epub 2019 Sep 27.

Authors

Marisa B Brizzi¹, Thomas D Chiampas¹, Sarah M Michienzi¹, Jeremy D Young², Mahesh C Patel², Melissa E Badowski¹

Affiliations

¹ Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA.
² Department of Medicine, Division of Infectious Diseases, Immunology and Internal Medicine, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA.

PMID: 31558124
DOI: 10.1177/0956462419863925

No abstract available

Keywords: HIV/AIDS; adverse effects; antiretroviral therapy; dolutegravir.

MeSH terms

Adult
Anti-HIV Agents / administration & dosage*
Anti-HIV Agents / pharmacology
Dideoxynucleosides / administration & dosage*
Dideoxynucleosides / pharmacology
Drug Combinations
Drug Therapy, Combination
Drug-Related Side Effects and Adverse Reactions
Female
HIV Infections / drug therapy*
HIV Infections / virology
Heterocyclic Compounds, 3-Ring / administration & dosage*
Heterocyclic Compounds, 3-Ring / pharmacology
Humans
Illinois
Lamivudine / administration & dosage*
Lamivudine / pharmacology
Male
Middle Aged
Oxazines
Piperazines
Prisoners / statistics & numerical data*
Prisons
Pyridones
Retrospective Studies
Treatment Outcome

Substances

Anti-HIV Agents
Dideoxynucleosides
Drug Combinations
Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
Lamivudine
dolutegravir
abacavir